RESUMEN
Purpose: This work aims to determine whether previously defined genotype risk groups interact with Age-Related Eye Disease Study formulation (AREDS-F) use in progression to neovascular age-related macular degeneration (nvAMD). Methods: We conducted a case-only study of 265 nvAMD patients. Patients were anonymously genotyped at the complement factor H and age-related maculopathy susceptibility 2 loci and segregated into genotype groups (GTGs) defined by specific combinations of risk alleles. Physicians, who were blind to patients' GTGs, obtained patients' AREDS-F use history. The facility performing genetic analysis was blind to the AREDS-F use history. We used logistic analysis to estimate the interaction coefficient between AREDS-F use and GTG 2 vs GTG 3 in a general-population model. Results: The odds ratio of numbers of patients reporting prior AREDS-F use to nonuse for GTG 2 vs GTG 3 was 4.18 (P = .001). Logistic regression, correcting for nongenetic risk factors, gave an estimate of the ß for interaction of AREDS-F with genotype of 1.57 (P = .001). This estimates a corrected odds ratio associated with the effect of interaction of 4.81 between those in GTG 2 compared with those in GTG 3. Conclusions: Our data indicate an interaction between GTGs and AREDS-F use that is consistent in size and direction with previously published reports, which had found that using AREDS-F supplements significantly increases the risk of nvAMD for some users and significantly protects other users.
RESUMEN
Two patients with orbital trauma and intraorbital foreign bodies, as seen on a computed tomography scan, were taken to the operating room to rule out occult ruptured globe with possible foreign body removal. The C-arm fluoroscopic unit was employed to obtain real-time images of the foreign body's location in relation to the surgeon's dissection tools and the foreign body was extracted with minimal dissection and operating time. When removal of a foreign body is warranted, intraoperative fluoroscopy can help reduce surgical time and orbital manipulation.
Asunto(s)
Cuerpos Extraños en el Ojo/diagnóstico por imagen , Lesiones Oculares Penetrantes/diagnóstico por imagen , Metales , Órbita/diagnóstico por imagen , Órbita/lesiones , Heridas por Arma de Fuego/diagnóstico por imagen , Adulto , Niño , Cuerpos Extraños en el Ojo/cirugía , Lesiones Oculares Penetrantes/cirugía , Fluoroscopía , Humanos , Cuidados Intraoperatorios , Masculino , Tomografía Computarizada por Rayos X , Heridas por Arma de Fuego/cirugíaRESUMEN
The development of increasingly refined vitreoretinal surgical techniques has resulted in a variety of surgical procedures for age-related macular degeneration (AMD). These have included submacular surgery with removal of choroidal neovascular membranes and subretinal blood, intraoperative lysis of feeder vessels, pneumatic displacement of subretinal blood and macular translocation surgery. The goals of these procedures have been to improve upon the poor natural history of exudative AMD and restore useful central vision. This article reviews the varied approaches, results and complications of the surgical management of AMD.
Asunto(s)
Coagulación con Láser/métodos , Degeneración Macular/cirugía , Coroides/cirugía , Humanos , Mácula Lútea/cirugía , Resultado del TratamientoRESUMEN
PURPOSE OF REVIEW: To provide a current update on the use of intravitreal corticosteroids as a treatment for a variety of retinal diseases. RECENT FINDINGS: Pharmacokinetic studies demonstrate that a single 4 mg injection of intravitreal triamcinolone acetonide is present in the vitreous for up to 3 months. Many recent studies demonstrate a significant reduction in macular edema often with a significant improvement in vision for up to several months followed by a waning of treatment effect and recurrence of macular edema. Retreatments have been shown to be efficacious. Intravitreal triamcinolone acetonide may help lead to a reduction in subfoveal hard exudates in diffuse diabetic macular edema. It has been shown to be a more potent treatment than sub-Tenon's and retrobulbar triamcinolone acetonide for persistent macular edema. It may also be a significant adjunctive treatment for choroidal neovascularization treated with photodynamic therapy. Intravitreal corticosteroid implants have also been shown to be beneficial in early trials for persistent macular edema. SUMMARY: Intravitreal triamcinolone acetonide provides a potent short-term treatment for persistent macular edema and may be a useful adjunctive treatment for choroidal neovascularization. It remains to be determined whether intravitreal corticosteroids can provide long-term visual gain or stabilization. The side-effect profile of intravitreal corticosteroids is significant with corticosteroid-induced intraocular pressure rises. With longer-term studies, the rate of posterior subcapsular cataract formation is higher than previously reported, and there is a small but potential risk of endophthalmitis.